Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker

26 Oct 2016

Abstract excerpt

Cholangiocarcinoma (CCA) is a devastating disease due to resistance to traditional chemotherapies and radiotherapies. New therapeutic strategies against CCA are urgently needed. This study investigated the role of lipocalin-2 (LCN2) in human cholangiocarcinoma as a potential therapeutic target and diagnostic marker. So far, the role of LCN2 in cancer is still controversial and studies regarding the role of LCN2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Mechanisms of cancer metastasis
Share to Metastasis and carcinoma case studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27782193
DOI: 10.1038/srep36138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic markerPMID 27782193Read ↗

Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progressionSemantic proximity Read ↗

N‐myc downstream‐regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA‐181c negative feedback pathwaySemantic proximity Read ↗

Lipocalin2 suppresses metastasis of colorectal cancer by attenuating NF-κB-dependent activation of snail and epithelial mesenchymal transitionSemantic proximity Read ↗

ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in CholangiocarcinomaSemantic proximity Read ↗

Lipocalin-2 negatively regulates epithelial–mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancerSemantic proximity Read ↗

Integrative Identification and Validation of Exosome-Related Genes as Diagnostic Biomarkers and Potential Therapeutic Targets in CholangiocarcinomaSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expressionSemantic proximity Read ↗

ACSL3 is an unfavorable prognostic marker in cholangiocarcinoma patients and confers ferroptosis resistance in cholangiocarcinoma cellsSemantic proximity Read ↗

Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in CholangiocarcinomaSemantic proximity Read ↗

Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinomaSemantic proximity Read ↗

<i>In vitro</i> and <i>in vivo</i> evidences propound therapeutic potential of Lipocalin 2 in cervical carcinomaSemantic proximity Read ↗

Long non-coding RNA LINC00152 regulates cell proliferation and migration by epigenetically repressing LRIG1 expression in cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.